Immunotherapy in Glioblastoma: An Overview of Current Status.

Clin Pharmacol · 2025 · PMC12305673 · PMID 40735070

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Moreover, considering the development of biomarker-driven approaches and personalized therapies, there may be significant promise in achieving differential success against GB.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.